Respiratory syncytial virus (RSV) is a significant cause of disease in the young and old. Recently, pre-fusion F protein vaccines for RSV have received food and drug administration (FDA) approval to protect adults aged 60 years and older; however, vaccines evaluated against RSV typically do not elicit complete or durable protective immunity. We previously showed that an RSV G protein central conserved domain (CCD) nanoparticle vaccine containing an S177Q mutation (NP-S177Q) induced favorable immunogenicity and RSV-neutralizing antibodies compared with RSV G protein vaccination alone in mice. Boosting BALB/c mice with NP-S177Q vaccines improved correlates of protection and reduced markers of immunopathology following RSV challenge. This study examined microparticle (MP) vaccines displaying the CCD with an RSV G S177Q mutation (MP-S177Q) adjuvanted with monophosphoryl lipid A (MPLA) in BALB/c mice. Our findings show that mice adjuvanted MP-S177Q vaccination develop effective viral neutralization compared with MP-WT and MP-S177Q vaccination and have improved bronchoalveolar Th1-type cytokine responses following the RSV challenge compared with MP-WT or vehicle-vaccinated mice. This study shows that a rationally mutated RSV G protein MP vaccine is safe, effective, and can advance precision RSV vaccines.
Get full access to this article
View all access options for this article.
References
1.
AcostaPL, CaballeroMT, PolackFP. Brief history and characterization of enhanced respiratory syncytial virus disease. Clin Vaccine Immunol, 2015; 23(3):189–195; doi: 10.1128/CVI.00609-15
2.
AndersonLJ, JadhaoSJ, PadenCR, et al.Functional features of the respiratory syncytial virus G protein. Viruses, 2021; 13(7); doi: 10.3390/v13071214
3.
BakreAA, HarcourtJL, HaynesLM, et al.The central conserved region (CCR) of respiratory syncytial virus (RSV) G protein modulates host miRNA expression and alters the cellular response to infection. Vaccines (Basel), 2017; 5(3); doi: 10.3390/vaccines5030016
4.
BembridgeGP, Garcia-BeatoR, LopezJA, et al.Subcellular site of expression and route of vaccination influence pulmonary eosinophilia following respiratory syncytial virus challenge in BALB/c mice sensitized to the attachment G protein. J Immunol, 1998; 161(5):2473–2480.
5.
BembridgeGP, LopezJA, BustosR, et al.Priming with a secreted form of the fusion protein of respiratory syncytial virus (RSV) promotes interleukin-4 (IL-4) and IL-5 production but not pulmonary eosinophilia following RSV challenge. J Virol, 1999; 73(12):10086–10094; doi: 10.1128/JVI.73.12.10086-10094.1999
6.
BergeronHC, HansenMR, TrippRA. Interferons-Implications in the immune response to respiratory viruses. Microorganisms, 2023a;11(9); doi: 10.3390/microorganisms11092179
7.
BergeronHC, KauvarLM, TrippRA. Anti-G protein antibodies targeting the RSV G protein CX3C chemokine region improve the interferon response. Ther Adv Infect Dis, 2023b;10:20499361231161157; doi: 10.1177/20499361231161157
8.
BergeronHC, MurrayJ, AroraA, et al.Immune prophylaxis targeting the respiratory syncytial virus (RSV) G protein. Viruses, 2023c;15(5); doi: 10.3390/v15051067
9.
BergeronHC, MurrayJ, JuarezMG, et al.Immunogenicity and protective efficacy of an RSV G S177Q central conserved domain nanoparticle vaccine. Front Immunol, 2023d;14:1215323; doi: 10.3389/fimmu.2023.1215323
10.
BergeronHC, MurrayJ, Nunez CastrejonAM, et al.Respiratory syncytial virus (RSV) G protein vaccines with central conserved domain mutations induce CX3C-CX3CR1 blocking antibodies. Viruses, 2021; 13(2); doi: 10.3390/v13020352
11.
BergeronHC, TrippRA. Immunopathology of RSV: An updated review. Viruses, 2021; 13(12); doi: 10.3390/v13122478
12.
BergeronHC, TrippRA. RSV replication, transmission, and disease are influenced by the RSV G protein. Viruses, 2022; 14(11); doi: 10.3390/v14112396
13.
Boyoglu-BarnumS, GastonKA, ToddSO, et al.A respiratory syncytial virus (RSV) anti-G protein F(ab’)2 monoclonal antibody suppresses mucous production and breathing effort in RSV rA2-line19F-infected BALB/c mice. J Virol, 2013; 87(20):10955–10967; doi: 10.1128/JVI.01164-13
14.
Boyoglu-BarnumS, ToddSO, ChirkovaT, et al.An anti-G protein monoclonal antibody treats RSV disease more effectively than an anti-F monoclonal antibody in BALB/c mice. Virology, 2015; 483:117–125; doi: 10.1016/j.virol.2015.02.035
15.
BukreyevA, YangL, CollinsPL. The secreted G protein of human respiratory syncytial virus antagonizes antibody-mediated restriction of replication involving macrophages and complement. J Virol, 2012; 86(19):10880–10884; doi: 10.1128/JVI.01162-12
16.
CaidiH, MiaoC, ThornburgNJ, et al.Anti-respiratory syncytial virus (RSV) G monoclonal antibodies reduce lung inflammation and viral lung titers when delivered therapeutically in a BALB/c mouse model. Antiviral Res, 2018; 154:149–157; doi: 10.1016/j.antiviral.2018.04.014
17.
ChirkovaT, Boyoglu-BarnumS, GastonKA, et al.Respiratory syncytial virus G protein CX3C motif impairs human airway epithelial and immune cell responses. J Virol, 2013; 87(24):13466–13479; doi: 10.1128/JVI.01741-13
18.
ChirkovaT, LinS, OomensAGP, et al.CX3CR1 is an important surface molecule for respiratory syncytial virus infection in human airway epithelial cells. J Gen Virol, 2015; 96(9):2543–2556; doi: 10.1099/vir.0.000218
19.
ConnorsM, GieseNA, KulkarniAB, et al.Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J Virol, 1994; 68(8):5321–5325; doi: 10.1128/JVI.68.8.5321-5325.1994
20.
FedechkinSO, GeorgeNL, Nunez CastrejonAM, et al.Conformational flexibility in respiratory syncytial virus g neutralizing epitopes. J Virol, 2020; 94(6); doi: 10.1128/JVI.01879-19
21.
FedechkinSO, GeorgeNL, WolffJT, et al.Structures of respiratory syncytial virus G antigen bound to broadly neutralizing antibodies. Sci Immunol, 2018; 3(21); doi: 10.1126/sciimmunol.aar3534
22.
FuentesS, CoyleEM, GoldingH, et al.Nonglycosylated G-Protein vaccine protects against homologous and heterologous respiratory syncytial Virus (RSV) challenge, while glycosylated G enhances RSV lung pathology and cytokine levels. J Virol, 2015; 89(16):8193–8205; doi: 10.1128/JVI.00133-15
23.
FulginitiVA, EllerJJ, DownieAW, et al.Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated measles virus vaccines. JAMA, 1967; 202(12):1075–1080; doi: 10.1001/jama.202.12.1075
HallCB. The burgeoning burden of respiratory syncytial virus among children. Infect Disord Drug Targets, 2012; 12(2):92–97; doi: 10.2174/187152612800100099
26.
HarcourtJ, AlvarezR, JonesLP, et al.Respiratory syncytial virus G protein and G protein CX3C motif adversely affect CX3CR1+ T cell responses. J Immunol, 2006; 176(3):1600–1608; doi: 10.4049/jimmunol.176.3.1600
27.
HarcourtJL, KarronRA, TrippRA. Anti-G protein antibody responses to respiratory syncytial virus infection or vaccination are associated with inhibition of G protein CX3C-CX3CR1 binding and leukocyte chemotaxis. J Infect Dis, 2004; 190(11):1936–1940; doi: 10.1086/425516
28.
HaynesLM, CaidiH, RaduGU, et al.Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (RSV) G protein mediates viral clearance and reduces the pathogenesis of RSV infection in BALB/c mice. J Infect Dis, 2009; 200(3):439–447; doi: 10.1086/600108
29.
HaynesLM, JonesLP, BarskeyA, et al.Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P. J Virol, 2003; 77(18):9831–9844; doi: 10.1128/jvi.77.18.9831-9844.2003
30.
HijanoDR, VuLD, KauvarLM, et al.Role of type i interferon (IFN) in the respiratory syncytial virus (RSV) immune response and disease severity. Front Immunol, 2019; 10:566; doi: 10.3389/fimmu.2019.00566
31.
JeongKI, PiepenhagenPA, KishkoM, et al.CX3CR1 is expressed in differentiated human ciliated airway cells and co-localizes with respiratory syncytial virus on cilia in a g protein-dependent manner. PLoS One, 2015; 10(6):e0130517; doi: 10.1371/journal.pone.0130517
32.
JohnsonSM, McNallyBA, IoannidisI, et al.Respiratory syncytial virus uses CX3CR1 as a receptor on primary human airway epithelial cultures. PLoS Pathog, 2015; 11(12):e1005318; doi: 10.1371/journal.ppat.1005318
33.
JohnsonTR, GrahamBS. Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection. Pediatr Infect Dis J, 2004; 23(1 Suppl):S46–S57; doi: 10.1097/01.inf.0000108192.94692.d2
34.
JorgensenSCJ. Nirsevimab: Review of pharmacology, antiviral activity and emerging clinical experience for respiratory syncytial virus infection in infants. J Antimicrob Chemother, 2023; 78(5):1143–1149; doi: 10.1093/jac/dkad076
35.
JorqueraPA, ChoiY, OakleyKE, et al.Nanoparticle vaccines encompassing the respiratory syncytial virus (RSV) G protein CX3C chemokine motif induce robust immunity protecting from challenge and disease. PLoS One, 2013; 8(9):e74905; doi: 10.1371/journal.pone.0074905
36.
JorqueraPA, OakleyKE, PowellTJ, et al.Layer-by-layer nanoparticle vaccines carrying the G Protein CX3C motif protect against RSV infection and disease. Vaccines (Basel), 2015; 3(4):829–849; doi: 10.3390/vaccines3040829
37.
JorqueraPA, TrippRA. Synthetic biodegradable microparticle and nanoparticle vaccines against the respiratory syncytial virus. Vaccines (Basel), 2016; 4(4); doi: 10.3390/vaccines4040045
38.
KampmannB, MadhiSA, MunjalI, et al.; MATISSE Study Group. Bivalent prefusion F vaccine in pregnancy to prevent RSV Illness in infants. N Engl J Med, 2023; 388(16):1451–1464; doi: 10.1056/NEJMoa2216480
39.
KimHW, CancholaJG, BrandtCD, et al.Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol, 1969; 89(4):422–434; doi: 10.1093/oxfordjournals.aje.a120955
40.
LeeY, KlenowL, CoyleEM, et al.Monoclonal antibodies targeting sites in respiratory syncytial virus attachment G protein provide protection against RSV-A and RSV-B in mice. Nat Commun, 2024; 15(1):2900; doi: 10.1038/s41467-024-47146-2
41.
LiangB, KabatovaB, KabatJ, et al.Effects of alterations to the CX3C motif and secreted form of human respiratory syncytial virus (RSV) G protein on immune responses to a parainfluenza virus vector expressing the RSV G protein. J Virol, 2019; 93(7); doi: 10.1128/JVI.02043-18
42.
McLellanJS, RayWC, PeeplesME. Structure and function of respiratory syncytial virus surface glycoproteins. Curr Top Microbiol Immunol, 2013; 372:83–104; doi: 10.1007/978-3-642-38919-1_4
43.
MurphyBR, WalshEE. Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. J Clin Microbiol, 1988; 26(8):1595–1597; doi: 10.1128/jcm.26.8.1595-1597.1988
Nunez CastrejonAM, O’RourkeSM, KauvarLM, et al.Structure-based design and antigenic validation of respiratory syncytial virus g immunogens. J Virol, 2022; 96(7):e0220121; doi: 10.1128/jvi.02201-21
46.
PowellTJ, JacobsA, TangJ, et al.Microparticle RSV vaccines presenting the g protein CX3C chemokine motif in the context of tlr signaling induce protective Th1 immune responses and prevent pulmonary eosinophilia post-challenge. Vaccines (Basel), 2022; 10(12); doi: 10.3390/vaccines10122078
47.
PowellTJ, PalathN, DeRomeME, et al.Synthetic nanoparticle vaccines produced by layer-by-layer assembly of artificial biofilms induce potent protective T-cell and antibody responses in vivo. Vaccine, 2011; 29(3):558–569; doi: 10.1016/j.vaccine.2010.10.001
RoeMK, PerezMA, HsiaoHM, et al.An RSV Live-Attenuated vaccine candidate lacking G protein mucin domains is attenuated, immunogenic, and effective in preventing RSV in BALB/c Mice. J Infect Dis, 2022; 227(1):50–60; doi: 10.1093/infdis/jiac382
50.
RuckwardtTJ. The road to approved vaccines for respiratory syncytial virus. NPJ Vaccines, 2023; 8(1):138; doi: 10.1038/s41541-023-00734-7
51.
SridharS, LuedtkeA, LangevinE, et al.Effect of dengue serostatus on dengue vaccine safety and efficacy. N Engl J Med, 2018; 379(4):327–340; doi: 10.1056/NEJMoa1800820
TrippRA, PowerUF, OpenshawPJM, et al.Respiratory syncytial virus: Targeting the G protein provides a new approach for an old problem. J Virol, 2018; 92(3); doi: 10.1128/JVI.01302-17
54.
UrsinRL, KleinSL. Sex differences in respiratory viral pathogenesis and treatments. Annu Rev Virol, 2021; 8(1):393–414; doi: 10.1146/annurev-virology-091919-092720
55.
VoorzaatR, CoxF, van OverveldD, et al.Design and preclinical evaluation of a nanoparticle vaccine against respiratory syncytial virus based on the attachment protein G. Vaccines (Basel), 2024; 12(3); doi: 10.3390/vaccines12030294
56.
WarisME, TsouC, ErdmanDD, et al.Respiratory synctial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J Virol, 1996; 70(5):2852–2860; doi: 10.1128/JVI.70.5.2852-2860.1996
57.
ZhangL, PeeplesME, BoucherRC, et al.Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. J Virol, 2002; 76(11):5654–5666; doi: 10.1128/jvi.76.11.5654-5666.2002
58.
ZhaoriG. Nirsevimab brings breakthrough in the prevention of respiratory syncytial virus infection in infants – Importance of design. Pediatr Investig, 2023; 7(2):144–146; doi: 10.1002/ped4.12377
59.
ZhivakiD, LemoineS, LimA, et al.Respiratory syncytial virus infects regulatory B cells in human neonates via chemokine receptor CX3CR1 and promotes lung disease severity. Immunity, 2017; 46(2):301–314; doi: 10.1016/j.immuni.2017.01.010
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
